产品
编 号：F580368
分子式：C19H15N3O5
分子量：365.34
分子式：C19H15N3O5
分子量：365.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 919091-63-7
产品详情
生物活性：
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells.
体内研究：
RA-9 (5 mg/kg；腹腔注射；服用一天，停药两天) 在卵巢癌小鼠模型中抑制体内人卵巢癌细胞生长并延长存活期。Animal Model:Six-week-old female immunodeficient (NCr nu/nu) mice
Dosage:5 mg/kg
Administration:I.p; one-day on, two-days off
Result:Significant reduction in tumor burden at day 12.
体外研究：
RA-9 (10-30 μM；48 小时) 抑制卵巢癌细胞系和原代培养物的生长。 RA-9 (1.25-5 μM；18 小时) 导致卵巢癌细胞中的细胞周期停滞和半胱天冬酶介导的细胞凋亡。 RA-9 (5 μM；0-24 小时) 诱导卵巢癌细胞中的内质网应激反应。 RA-9 (5 μM；超过 24 小时) 处理结果与时间依赖性的 PARP 切割形成的积累早在 8 小时就很明显。
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells.
体内研究：
RA-9 (5 mg/kg；腹腔注射；服用一天，停药两天) 在卵巢癌小鼠模型中抑制体内人卵巢癌细胞生长并延长存活期。Animal Model:Six-week-old female immunodeficient (NCr nu/nu) mice
Dosage:5 mg/kg
Administration:I.p; one-day on, two-days off
Result:Significant reduction in tumor burden at day 12.
体外研究：
RA-9 (10-30 μM；48 小时) 抑制卵巢癌细胞系和原代培养物的生长。 RA-9 (1.25-5 μM；18 小时) 导致卵巢癌细胞中的细胞周期停滞和半胱天冬酶介导的细胞凋亡。 RA-9 (5 μM；0-24 小时) 诱导卵巢癌细胞中的内质网应激反应。 RA-9 (5 μM；超过 24 小时) 处理结果与时间依赖性的 PARP 切割形成的积累早在 8 小时就很明显。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备